Trostberg, May 19, 2020 - The Management Board and Supervisory Board of AlzChem Group AG, a vertically integrated specialty chemicals supplier with a leading market position in selected niche markets, received strong support from the shareholders attending today's virtual Annual General Meeting. All agenda items were approved by a large majority in the interest of the administration. Among other things, the Management Board and the Supervisory Board were discharged and the proposal for the appropriation of the balance sheet profit was approved, which provided for a dividend payment of EUR 0.75 per share. In addition, the existing Supervisory Board with its members Markus Zöllner (Chairman), Prof. Dr. Martina Heigl-Murauer, Dr. Caspar Freiherr von Schnurbein and Steve Röper was confirmed in office for another five years.

"We have a gratifying fiscal year 2019 behind us. In that year, we have been able to complete two major investment projects on schedule with the expansion of nitrile production and the commissioning of the new Creamino^(R) plant, which will have a major impact on our future. In addition, we have taken a major step forward with the own distribution of Creamino^(R), to which our customers have responded very positively," explained Andreas Niedermaier, CEO of AlzChem Group AG. "The first quarter of 2020 also developed positively, as we were able to compensate almost completely for the economic effects of the COVID-19 pandemic, primarily due to our highly diversified product portfolio. We are pleased that our shareholders appreciate this development."

The voting results of the Annual General Meeting can be viewed on the company's website at https://www.alzchem.com/de/hv.

About AlzChem Group AG
The AlzChem Group is a vertically integrated manufacturer of chemical products based on the so-called NCN chain. These are products with typical nitrogen-carbon-nitrogen bonding that are used in a wide variety of different industries. The Group has a leading position in select niche markets. The strategic focus of growth and the main focus of its extensive research and development are on the business segment Specialty Chemicals. The company has around 1,620 employees at four sites in Germany and three other sites abroad.